The potential rescheduling of cannabinoids, particularly at the federal level, is generating considerable excitement within the industry. A shift away from Schedule I status, often viewed as outdated and hindering progress, could unlock significant avenues for ventures. Reduced regulatory impediments, alongside greater access to banking and funding